{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["CADD", "MD simulations", "VEGFR-2 inhibitors", "apoptosis", "docking", "thieno[2,3-d]pyrimidine"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37232504", "DateCompleted": {"Year": "2023", "Month": "09", "Day": "13"}, "DateRevised": {"Year": "2023", "Month": "09", "Day": "20"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "05", "Day": "26"}], "Language": ["eng"], "ELocationID": ["10.1002/ddr.22083"], "Journal": {"ISSN": "1098-2299", "JournalIssue": {"Volume": "84", "Issue": "6", "PubDate": {"Year": "2023", "Month": "Sep"}}, "Title": "Drug development research", "ISOAbbreviation": "Drug Dev Res"}, "ArticleTitle": "A novel thieno[2,3-d]pyrimidine derivative inhibiting vascular endothelial growth factor receptor-2: A story of computer-aided drug discovery.", "Pagination": {"StartPage": "1247", "EndPage": "1265", "MedlinePgn": "1247-1265"}, "Abstract": {"AbstractText": ["Following the pharmacophoric features of vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitors, a novel thieno[2,3-d]pyrimidine derivative has been designed and its activity against VEGFR-2 has been demonstrated by molecular docking studies that showed an accurate binding mode and an excellent binding energy. Furthermore, the recorded binding was confirmed by a series of molecular dynamics simulation studies, which also revealed precise energetic, conformational, and dynamic changes. Additionally, molecular mechanics with generalized Born and surface area solvation and polymer-induced liquid precursors studies were conducted and verified the results of the MD simulations. Next, in silico absorption, distribution, metabolism, excretion, and toxicity studies have also been conducted to examine the general drug-like nature of the designed candidate. According to the previous results, the thieno[2,3-d]pyrimidine derivative was synthesized. Fascinatingly, it inhibited VEGFR-2 (IC<sub>50</sub> \u2009=\u200968.13\u2009nM) and demonstrated strong inhibitory activity toward human liver (HepG2), and prostate (PC3) cell lines with IC<sub>50</sub> values of 6.60 and 11.25\u2009\u00b5M, respectively. As well, it was safe and showed a high selectivity index against normal cell lines (WI-38). Finally, the thieno[2,3-d]pyrimidine derivative arrested the growth of the HepG2 cells at the G2/M phase inducing both early and late apoptosis. These results were further confirmed through the ability of the thieno[2,3-d]pyrimidine derivative to induce significant changes in the apoptotic genes levels of caspase-3, caspase-9, Bcl-2 associated X-protein, and B-cell lymphoma 2."], "CopyrightInformation": "\u00a9 2023 Wiley Periodicals LLC."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Menoufia University, Menoufia, Shibin-Elkom, Egypt."}], "LastName": "Sobh", "ForeName": "Eman A", "Initials": "EA"}, {"Identifier": ["0000-0002-2016-0728"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}], "LastName": "Dahab", "ForeName": "Mohammed A", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Bshra A", "Initials": "BA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biophysics Department, Faculty of Science, Cairo University, Cairo, Egypt."}], "LastName": "Ibrahim", "ForeName": "Ibrahim M", "Initials": "IM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Drug Dev Res", "NlmUniqueID": "8204468", "ISSNLinking": "0272-4391"}, "ChemicalList": [{"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Vascular Endothelial Growth Factor Receptor-2"}, {"RegistryNumber": "0", "NameOfSubstance": "Vascular Endothelial Growth Factor A"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrimidines"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": ["metabolism"], "DescriptorName": "Vascular Endothelial Growth Factor Receptor-2"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Vascular Endothelial Growth Factor A"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Drug Design"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Drug Discovery"}, {"QualifierName": ["pharmacology", "chemistry"], "DescriptorName": "Pyrimidines"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Abdelaziz, A., & Vaishampayan, U. (2017). Cabozantinib for the treatment of kidney cancer. Expert Review of Anticancer Therapy, 17(7), 577-584."}, {"Citation": "Abdelhaleem, E. F., Abdelhameid, M. K., Kassab, A. E., & Kandeel, M. M. (2018). Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. European Journal of Medicinal Chemistry, 143, 1807-1825."}, {"Citation": "Aborehab, N. M., Elnagar, M. R., & Waly, N. E. (2020). Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. Journal of Biochemical and Molecular Toxicology, 35(2), e22638."}, {"Citation": "Adly, M. E., Gedawy, E. M., El-Malah, A. A., & El-Telbany, F. A. (2018). Synthesis of novel Thieno[2,3-d]pyrimidine derivatives and evaluation of their cytotoxicity and EGFR inhibitory activity. Anti-Cancer Agents in Medicinal Chemistry, 18(5), 747-756."}, {"Citation": "Alanazi, M. M., Elkady, H., Alsaif, N. A., Obaidullah, A. J., Alanazi, W. A., Al-Hossaini, A. M., Alharbi, M. A., Eissa, I. H., & Dahab, M. A. (2022). Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: Design, synthesis, and in silico study. Journal of Molecular Structure, 1253, 132220."}, {"Citation": "Alanazi, M. M., Mahdy, H. A., Alsaif, N. A., Obaidullah, A. J., Alkahtani, H. M., Al-Mehizia, A. A., Alsubaie, S. M., Dahab, M. A., & Eissa, I. H. (2021). New bis ([1, 2, 4] triazolo)[4, 3-a: 3\u2032, 4\u2032-c] quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation. Bioorganic Chemistry, 112, 104949."}, {"Citation": "Al-Rashood, S. T., Hamed, A. R., Hassan, G. S., Alkahtani, H. M., Almehizia, A. A., Alharbi, A., Al-Sanea, M. M., & Eldehna, W. M. (2020). Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 831-839."}, {"Citation": "Alsaif, N. A., Dahab, M. A., Alanazi, M. M., Obaidullah, A. J., Al-Mehizia, A. A., Alanazi, M. M., Aldawas, S., Mahdy, H. A., & Elkady, H. (2021). New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis. Bioorganic Chemistry, 110, 104807."}, {"Citation": "Alsaif, N. A., Taghour, M. S., Alanazi, M. M., Obaidullah, A. J., Alanazi, W. A., Alasmari, A., Albassam, H., Dahab, M. A., & Mahdy, H. A. (2021). Identification of new [1, 2, 4] triazolo [4, 3-a] quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Bioorganic & Medicinal Chemistry, 46, 116384."}, {"Citation": "Antonsson, B., Conti, F., Ciavatta, A., Montessuit, S., Lewis, S., Martinou, I., Bernasconi, L., Bernard, A., Mermod, J.-J., Mazzei, G., Maundrell, K., Gambale, F., Sadoul, R., & Martinou, J. C. (1997). Inhibition of Bax channel-forming activity by Bcl-2. Science, 277(5324), 370-372."}, {"Citation": "Balah, A., Ezzat, O., & Akool, E.-S. (2018). Vitamin E inhibits cyclosporin a-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-\u03b2/Smad signaling pathway in rat liver. International Immunopharmacology, 65, 493-502."}, {"Citation": "Bergh, J., Bondarenko, I. M., Lichinitser, M. R., Liljegren, A., Greil, R., Voytko, N. L., Makhson, A. N., Cortes, J., Lortholary, A., Bischoff, J., Chan, A., Delaloge, S., Huang, X., Kern, K. A., & Giorgetti, C. (2012). First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study. Journal of Clinical Oncology, 30(9), 921-929."}, {"Citation": "Borenfreund, E., & Puerner, J. A. (1985). Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicology Letters, 24(2-3), 119-124."}, {"Citation": "Cheng, A. L., Kang, Y. K., Lin, D. Y., Park, J. W., Kudo, M., Qin, S., Chung, H. C., Song, X., Xu, J., Poggi, G., Omata, M., Pitman Lowenthal, S., Lanzalone, S., Yang, L., Lechuga, M. J., & Raymond, E. (2013). Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. Journal of Clinical Oncology, 31(32), 4067-4075."}, {"Citation": "Cheng, E. H. Y. A., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., & Korsmeyer, S. J. (2001). BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Molecular Cell, 8(3), 705-711."}, {"Citation": "Crawford, E. D., & Wells, J. A. (2011). Caspase substrates and cellular remodeling. Annual Review of Biochemistry, 80, 1055-1087."}, {"Citation": "Dearden, J. C. (2003). In silico prediction of drug toxicity. Journal of Computer-Aided Molecular Design, 17(2), 119-127."}, {"Citation": "Denizot, F., & Lang, R. (1986). Rapid colorimetric assay for cell growth and survival. Journal of Immunological Methods, 89(2), 271-277."}, {"Citation": "Eissa, I. H., Alesawy, M. S., Saleh, A.M., Elkaeed, E. B., Alsfouk, B. A., El-Attar, A. A. M. M., & Metwaly, A. M. (2022). Ligand and structure-based in silico determination of the most promising SARS-CoV-2 nsp16-nsp10 2\u2032-o-Methyltransferase complex inhibitors among 3009 FDA approved drugs. Molecules, 27(7), 2287."}, {"Citation": "Eissa, I. H., Khalifa, M. M., Elkaeed, E. B., Hafez, E. E., Alsfouk, A. A., & Metwaly, A. M. (2021). In silico exploration of potential natural inhibitors against SARS-Cov-2 nsp10. Molecules, 26(20), 6151."}, {"Citation": "El-Adl, K., Sakr, H. M., Yousef, R. G., Mehany, A. B. M., Metwaly, A. M., Elhendawy, M. A., Radwan, M. M., ElSohly, M. A., Abulkhair, H. S., & Eissa, I. H. (2021). Discovery of new quinoxaline-2 (1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. Bioorganic Chemistry, 114, 105105."}, {"Citation": "Eldehna, W. M., Hassan, G. S., Al-Rashood, S. T., Al-Warhi, T., Altyar, A. E., Alkahtani, H. M., Almehizia, A. A., & Abdel-Aziz, H. A. (2019). Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 34(1), 322-332."}, {"Citation": "Elkady, H., Elwan, A., El-Mahdy, H. A., Doghish, A. S., Ismail, A., Taghour, M. S., Elkaeed, E. B., Eissa, I. H., Dahab, M. A., Mahdy, H. A., & Khalifa, M. M. (2022). New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 403-416."}, {"Citation": "Elkaeed, E. B., Elkady, H., Belal, A., Alsfouk, B. A., Ibrahim, T. H., Abdelmoaty, M., Arafa, R. K., Metwaly, A. M., & Eissa, I. H. (2022). Multi-phase in silico discovery of potential SARS-CoV-2 RNA-dependent RNA polymerase inhibitors among 3009 clinical and FDA-approved related drugs. Processes, 10(3), 530."}, {"Citation": "Elkaeed, E. B., Khalifa, M. M., Alsfouk, B. A., Alsfouk, A. A., El-Attar, A.-A. M., Eissa, I. H., & Metwaly, A. M. (2022). The discovery of potential SARS-CoV-2 natural inhibitors among 4924 African metabolites targeting the papain-like protease: A multi-phase in silico approach. Metabolites, 12(11), 1122."}, {"Citation": "Elkaeed, E. B., Taghour, M. S., Mahdy, H. A., Eldehna, W. M., El-Deeb, N. M., Kenawy, A. M., Alsfouk, B. A., Dahab, M. A., Metwaly, A. M., Eissa, I. H., & El-Zahabi, M. A. (2022). New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: Design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 2191-2205."}, {"Citation": "Elkaeed, E. B., Yousef, R. G., Elkady, H., Gobaara, I. M. M., Alsfouk, B. A., Husein, D. Z., Ibrahim, I. M., Metwaly, A. M., & Eissa, I. H. (2022). Design, synthesis, docking, DFT, MD simulation studies of a new nicotinamide-based derivative: In vitro anticancer and VEGFR-2 inhibitory effects. Molecules, 27(14), 4606."}, {"Citation": "Elkaeed, E. B., Youssef, F. S., Eissa, I. H., Elkady, H., Alsfouk, A. A., Ashour, M. L., El Hassab, M. A., Abou-Seri, S. M., & Metwaly, A. M. (2022). Multi-step in silico discovery of natural drugs against COVID-19 targeting main protease. International Journal of Molecular Sciences, 23(13), 6912."}, {"Citation": "Elmetwally, S. A., Saied, K. F., Eissa, I. H., & Elkaeed, E. B. (2019). Design, synthesis and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorganic Chemistry, 88, 102944."}, {"Citation": "Elnagar, M. R., Walls, A. B., Helal, G. K., Hamada, F. M., Thomsen, M. S., & Jensen, A. A. (2018). Functional characterization of \u03b17 nicotinic acetylcholine and NMDA receptor signaling in SH-SY5Y neuroblastoma cells in an ERK phosphorylation assay. European Journal of Pharmacology, 826, 106-113."}, {"Citation": "Elwan, A., Abdallah, A. E., Mahdy, H. A., Dahab, M. A., Taghour, M. S., Elkaeed, E. B., Mehany, A. B., Nabeeh, A., Adel, M., & Alsfouk, A. A. (2022a). Modified benzoxazole-based VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, and anti-proliferative evaluation. Molecules, 27(15), 5047."}, {"Citation": "Elwan, A., Abdallah, A. E., Mahdy, H. A., Dahab, M. A., Taghour, M. S., Elkaeed, E. B., Mehany, A. B., Nabeeh, A., Adel, M., & Alsfouk, A. A. J. M. (2022b). Modified benzoxazole-based VEGFR-2 inhibitors and apoptosis inducers: Design synthesis, and anti-proliferative evaluation. Molecules, 27(15), 5047."}, {"Citation": "Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Staehler, M., Negrier, S., Chevreau, C., Desai, A. A., Rolland, F., Demkow, T., Hutson, T. E., Gore, M., Anderson, S., Hofilena, G., Shan, M., Pena, C., Lathia, C., & Bukowski, R. M. (2009). Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Journal of Clinical Oncology, 27(20), 3312-3318."}, {"Citation": "Ferreira, L. L. G., & Andricopulo, A. D. (2019). ADMET modeling approaches in drug discovery. Drug Discovery Today, 24(5), 1157-1165."}, {"Citation": "Goh, G. B., Hodas, N. O., & Vishnu, A. (2017). Deep learning for computational chemistry. Journal of Computational Chemistry, 38(16), 1291-1307."}, {"Citation": "Idakwo, G., Luttrell, J., Chen, M., Hong, H., Zhou, Z., Gong, P., & Zhang, C. (2018). A review on machine learning methods for in silico toxicity prediction. Journal of Environmental Science and Health, Part C, 36(4), 169-191."}, {"Citation": "Khalil, N. A., Ahmed, E. M., Zaher, A. F., El-Zoghbi, M. S., & Sobh, E. A. (2020). Synthesis of certain benzothieno[3,2-d]pyrimidine derivatives as a selective SIRT2 inhibitors. European Journal of Medicinal Chemistry, 187, 111926."}, {"Citation": "Kruhlak, N. L., Benz, R. D., Zhou, H., & Colatsky, T. J. (2012). (Q) SAR modeling and safety assessment in regulatory review. Clinical Pharmacology and Therapeutics, 91(3), 529-534."}, {"Citation": "Kuida, K. (2000). Caspase-9. The International Journal of Biochemistry & Cell Biology, 32(2), 121-124."}, {"Citation": "Lo, K. K.-W., Lee, T. K.-M., Lau, J. S.-Y., Poon, W.-L., & Cheng, S.-H. (2008). Luminescent biological probes derived from ruthenium (II) estradiol polypyridine complexes. Inorganic Chemistry, 47(1), 200-208."}, {"Citation": "Lyons, T. G. (2019). Targeted therapies for triple-negative breast cancer. Current Treatment Options in Oncology, 20, 82."}, {"Citation": "Metwaly, A. M., Elkaeed, E. B., Alsfouk, B. A., Saleh, A. M., Mostafa, A. E., & Eissa, I. H. (2022a). The computational preventive potential of the rare flavonoid, patuletin, isolated from tagetes patula, against SARS-CoV-2. Plants, 11(14), 1886."}, {"Citation": "Metwaly, A. M., Elwan, A., El-Attar, A.-A. M., Al-Rashood, S. T., & Eissa, I. H. (2022b). Structure-Based virtual screening, docking, ADMET, molecular dynamics, and MM-PBSA calculations for the discovery of potential natural SARS-CoV-2 helicase inhibitors from the traditional Chinese Medicine. Journal of Chemistry, 2022, 1."}, {"Citation": "Musumeci, F., Radi, M., Brullo, C., & Schenone, S. (2012). Vascular endothelial growth factor (VEGF) receptors: Drugs and new inhibitors. Journal of Medicinal Chemistry, 55(24), 10797-10822."}, {"Citation": "Nascimento, I. J. D. S., de Aquino, T. M., & da Silva-J\u00fanior, E. F. (2022). The new era of drug discovery: The power of computer-aided drug design (CADD). Letters in Drug Design & Discovery, 19(11), 951-955."}, {"Citation": "Norinder, U., & Bergstr\u00f6m, C. A. S. (2006). Prediction of ADMET properties. ChemMedChem, 1(9), 920-937."}, {"Citation": "Perlman, H., Zhang, X., Chen, M. W., Walsh, K., & Buttyan, R. (1999). An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death and Differentiation, 6(1), 48-54."}, {"Citation": "Sabt, A., Abdelhafez, O. M., El-Haggar, R. S., Madkour, H. M. F., Eldehna, W. M., El-Khrisy, E. E. D. A. M., Abdel-Rahman, M. A., & Rashed, L. A. (2018). Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: Synthesis, in vitro biological evaluation, and QSAR studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 33(1), 1095-1107."}, {"Citation": "Salvesen, G. S., & Riedl, S. J. (2008). Caspase mechanisms, programmed cell death in cancer progression and therapy. Springer, 615, 13-23."}, {"Citation": "Shearouse, W. C., Shumba, M. Z., Mack, J., & Solvent-Free, A. (2014). One-step, one-pot Gewald reaction for alkyl-aryl ketones via mechanochemistry. Applied Sciences, 4(2), 171-179."}, {"Citation": "Sobh, E. A., Khalil, N. A., Faggal, S. I., & Hassan, M. S. A. (2022). New benzothienopyrimidine derivatives as dual EGFR/ARO inhibitors: Design, synthesis, and their cytotoxic effect on MCF-7 breast cancer cell line. Drug Development Research, 83(5), 1075-1096."}, {"Citation": "Sapra Sharma, P., Sharma, R., & Tyagi, T. (2011). VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: Present and future. Current Cancer Drug Targets, 11(5), 624-653."}, {"Citation": "Suleimen, Y. M., Jose, R. A., Suleimen, R. N., Arenz, C., Ishmuratova, M., Toppet, S., Dehaen, W., Alsfouk, A. A., Elkaeed, E. B., Eissa, I. H., & Metwaly, A. M. (2022c). Isolation and in silico Anti-SARS-CoV-2 papain-Like protease potentialities of two rare 2-Phenoxychromone derivatives from artemisia spp. Molecules, 27(4), 1216."}, {"Citation": "Suleimen, Y. M., Jose, R. A., Suleimen, R. N., Arenz, C., Ishmuratova, M. Y., Toppet, S., Dehaen, W., Alsfouk, B. A., Elkaeed, E. B., Eissa, I. H., & Metwaly, A. H. (2022a). Jusanin, a new flavonoid from artemisia commutata with an in silico inhibitory potential against the SARS-CoV-2 main protease. Molecules, 27(5), 1636."}, {"Citation": "Suleimen, Y. M., Jose, R. A., Suleimen, R. N., Ishmuratova, M. Y., Toppet, S., Dehaen, W., Alsfouk, A. A., Elkaeed, E. B., Eissa, I. H., & Metwaly, A. M. (2022b). Isolation and in silico SARS-CoV-2 main protease inhibition potential of jusan coumarin, a new dicoumarin from artemisia glauca. Molecules, 27(7), 2281."}, {"Citation": "Taghour, M. S., Elkady, H., Eldehna, W. M., El-Deeb, N. M., Kenawy, A. M., Elkaeed, E. B., Alsfouk, A. A., Alesawy, M. S., Metwaly, A. M., & Eissa, I. H. (2022). Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: In-vitro anticancer evaluation and in-silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 1903-1917."}, {"Citation": "Taghour, M. S., Mahdy, H. A., Gomaa, M. H., Aglan, A., Eldeib, M. G., Elwan, A., Dahab, M. A., Elkaeed, E. B., Alsfouk, A. A., & Khalifa, M. M. (2022). Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and antiproliferative evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 2063-2077."}, {"Citation": "Wang, J., & Lenardo, M. J. (2000). Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. Journal of Cell Science, 113(5), 753-757."}, {"Citation": "Wang, X., Bove, A. M., Simone, G., & Ma, B. (2020). Molecular bases of VEGFR-2-mediated physiological function and pathological role. Frontiers in Cell and Developmental Biology, 8, 599281."}, {"Citation": "Zhang, J.-H., Zhang, Y., & Herman, B. (2003). Caspases, apoptosis and aging. Ageing Research Reviews, 2(4), 357-366."}, {"Citation": "Zhao, L., Ciallella, H. L., Aleksunes, L. M., & Zhu, H. (2020). Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling. Drug Discovery Today, 25(9), 1624-1638."}, {"Citation": "Zhu, C., Ma, X., Hu, Y., Guo, L., Chen, B., Shen, K., Xiao, Y. (2016). Safety and efficacy profile of lenvatinib in cancer therapy: A systematic review and meta-analysis. Oncotarget, 7(28), 44545-44557."}], "ReferenceList": [], "Title": "REFERENCES"}], "History": [{"Year": "2023", "Month": "5", "Day": "6"}, {"Year": "2023", "Month": "1", "Day": "22"}, {"Year": "2023", "Month": "5", "Day": "14"}, {"Year": "2023", "Month": "9", "Day": "13", "Hour": "6", "Minute": "41"}, {"Year": "2023", "Month": "5", "Day": "26", "Hour": "13", "Minute": "9"}, {"Year": "2023", "Month": "5", "Day": "26", "Hour": "8", "Minute": "3"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37232504", "10.1002/ddr.22083"]}}], "PubmedBookArticle": []}